# Samsung Bio business and ESG developments

> Developing situation record from CLSTR: https://clstr.news/situations/samsung-bio-business-and-esg-developments
> Updated: 2026-11-04T02:44:12.000Z. Sources: 4. Developments: 2.

Samsung Bioepis and Samsung Biologics have secured significant commercial agreements. Samsung Bioepis entered a partnership with Teva Pharmaceuticals International GmbH to commercialize two FDA-approved biosimilars, Renflexis and Eticovo, in the United States. This deal is valued at up to 420 million USD. Additionally, Samsung Biologics signed a long-term contract manufacturing agreement worth approximately 324.8 million USD, which is set to run until late 2031.

Following these commercial developments, Samsung Biologics received a “Negligible” ESG Risk Rating from Sustainalytics for 2026. The company ranked fourth out of 842 global pharmaceutical companies, placing it in the top 0.5 percent of its sector. The rating recognized the company for improvements in environmental management, social transparency, and governance.

## Timeline

### 2026-11-04: Samsung Biologics achieves top ESG risk rating from Sustainalytics

Samsung Biologics ranked 4th among 842 global pharmaceutical companies in the Sustainalytics 2026 ESG Risk Rating, achieving the highest “Negligible” risk status.

2 sources. https://clstr.news/cluster/samsung-biologics-achieves-top-esg-risk-rating-from-sustainalytics

### 2026-11-02: Samsung Bio Affiliates Secure Major Global Pharmaceutical Contracts

Samsung Bioepis signed a 420 million USD biosimilar commercialization deal with Teva, while Samsung Biologics secured a 324.8 million USD long-term manufacturing contract.

2 sources. https://clstr.news/cluster/samsung-bio-affiliates-secure-major-global-pharmaceutical-contracts

---
Cite as: Samsung Bio business and ESG developments. CLSTR, https://clstr.news/situations/samsung-bio-business-and-esg-developments